1. Home
  2. CINT vs PROK Comparison

CINT vs PROK Comparison

Compare CINT & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CI&T Inc

CINT

CI&T Inc

SELL

Current Price

$3.11

Market Cap

391.6M

Sector

Technology

ML Signal

SELL

Logo ProKidney Corp.

PROK

ProKidney Corp.

SELL

Current Price

$1.67

Market Cap

359.4M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
CINT
PROK
Founded
1995
2015
Country
Brazil
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
391.6M
359.4M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
CINT
PROK
Price
$3.11
$1.67
Analyst Decision
Buy
Buy
Analyst Count
10
7
Target Price
$5.62
★ $6.25
AVG Volume (30 Days)
55.4K
★ 1.4M
Earning Date
11-11-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $893,000.00
Revenue This Year
$16.56
N/A
Revenue Next Year
$9.87
$7.83
P/E Ratio
$17.94
★ N/A
Revenue Growth
N/A
★ 1075.00
52 Week Low
$2.80
$1.30
52 Week High
$6.06
$3.48

Technical Indicators

Market Signals
Indicator
CINT
PROK
Relative Strength Index (RSI) 46.66 49.14
Support Level $2.81 $1.55
Resistance Level $3.62 $1.76
Average True Range (ATR) 0.16 0.10
MACD 0.02 -0.00
Stochastic Oscillator 46.03 48.39

Price Performance

Historical Comparison
CINT
PROK

About CINT CI&T Inc

CI&T Inc operates as a partner in tech-integrated business solutions, helping organizations address complex challenges by integrating business approach, technology, and artificial intelligence into a single, coherent operating model. It is mainly engaged in the development of customizable software through the implementation of software solutions, including machine learning, artificial intelligence, data analytics, cloud migration and mobility technologies. The company provides technology services to various industry verticals, including Financial Services, Consumer Goods, Technology and Communications, Retail and Industrial Goods, Life Sciences, among others. The majority of the revenue is derived from providing technology services. Geographically, maximum revenue is derived from Brazil.

About PROK ProKidney Corp.

ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.

Share on Social Networks: